ArticleMolecular biology reports2026
Association between routine anticoagulation and pregnancy outcomes in women with heterozygous Factor V Leiden genotype.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundInherited thrombophilia, particularly heterozygous Factor V Leiden (G1691A) mutation, has been linked to placental vascular complications and adverse pregnancy outcomes. However, the benefit of antenatal anticoagulation in affected women without prior venous thromboembolism remains uncertain.
aimTo assess the association between antenatal anticoagulant therapy and pregnancy outcomes in women carrying the heterozygous Factor V Leiden genotype with a history of adverse pregnancy outcomes.
methodsThis case-control study included 200 pregnant women with confirmed heterozygous Factor V Leiden (G1691A) genotype. Participants were divided into two groups: those who received antenatal anticoagulation (low-molecular-weight heparin with or without low-dose aspirin; n = 100) and those who did not (n = 100). Genotyping was performed using real-time PCR and confirmed by Sanger sequencing. Pregnancy outcomes were compared, and relative risk (RR) with 95% confidence intervals (CI) calculated.
resultsBoth groups were comparable in baseline characteristics, including age, body mass index, and consanguinity (p > 0.05). Normal pregnancy outcomes were significantly higher in the anticoagulated group than controls (72% vs. 24%; p < 0.001). Anticoagulation was associated with a 2.7-fold higher likelihood of a normal pregnancy outcome (RR = 2.71, 95% CI: 1.94-3.78). Among adverse outcomes, only small for gestational age was significantly reduced (p = 0.02); other outcomes showed no significant differences.
conclusionAntenatal anticoagulant therapy was associated with improved pregnancy outcomes in women with heterozygous Factor V Leiden genotype. These findings support a potential benefit of prophylactic anticoagulation; however, confirmation through large prospective randomized trials is required.
Indexed as
Identifiers
42766054What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.